Nicole LaBrosse serves as Senior Vice President, Chief Financial Officer of Halozyme Therapeutics. She was appointed the Company's Chief Financial Officer on February 2, 2022, and has been with Halozyme since 2017.
On November 3, 2025, the Company announced a transition plan under which Ms. LaBrosse will continue to serve as Chief Financial Officer until the earlier of when a new chief financial officer is hired or March 30, 2026 (the "Separation Date"), and then depart to pursue a new professional opportunity; the Company stated her departure is not the result of any disagreement on financial statements, internal controls, operations, policies or practices. On November 18, 2025, the Company and Ms. LaBrosse entered into a Transition and Release Agreement. In 2025 she led two complex financial transactions, extending and increasing the Company's debt facility and completing the sale of $1.5 billion in aggregate principal amount of convertible senior notes, oversaw the return of approximately $342.3 million to stockholders through a share repurchase program, and played a key role in the financing, closing and integration of two acquisitions.